HER2-negative means the cancer cells lack, or have very low levels of, the HER2 protein. HER-2-low breast cancer is a subset within HER2-negative disease, which is still undergoing active research ...

Use of AI assistance reduced the misclassification of HER2-low and HER2-ultralow breast cancers as HER2-null by 24%, said study presenter Marina De Brot, MD, PhD, of AC Camargo Cancer Center in ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

HER2-low status is more frequent in HR-positive patients, and HER2-low rates increase as HR increases. In HER2-negative tumors, low HER2 expression is more often associated with favorable ...

Among a cohort of 1,135 women ages 40 and younger with stage I through III breast cancer, the incidence of LRR was 5.6%, with ...

The discordance rate amongst pathologists in evaluating HER2-low and HER2-ultralow breast cancers can reach 30%. "Our results show that across almost 2,000 readings, pathologists achieved a higher ...

Background: HER2 low status, defined as HER2 1+ or HER2 2+ and nonamplified by in-situ hybridization, has demonstrated the ability to identify a population of patients with triple-negative disease who ...

The DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan improved PFS over chemotherapy in ER+, HER2-low metastatic breast cancer.

For the HER2-overexpressing gastric cancer patients, DV + PD-1 + trastuzumab has the potential to become the new standard first-line treatment; for the HER2-low-expressing gastric cancer patients ...